综上可见,肿瘤免疫原性死亡可用于申请基金项目,因其相关研究不太多,且具有“可为肿瘤免疫研究提供新思路以及为肿瘤治疗提供新的方法和手段”的重大科学和临床意义。 参考文献:
1、Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. PMID: 29362479; PMCID: PMC5864239.
2、Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72. doi: 10.1146/annurev-immunol-032712-100008. Epub 2012 Nov 12. PMID: 23157435.
3、Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020 Nov 26;11(11):1013. doi: 10.1038/s41419-020-03221-2. PMID: 33243969; PMCID: PMC7691519.
4、Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017 Feb;17(2):97-111. doi: 10.1038/nri.2016.107. Epub 2016 Oct 17. PMID: 27748397.
5、Immunogenic cell stress and death. Nat Immunol. 2022 Apr;23(4):487-500. doi: 10.1038/s41590-022-01132-2. Epub 2022 Feb 10. PMID: 35145297.
原文链接: